Apr 26 |
Bristol, Sanofi, Takeda gain positive CHMP recommendations
|
Apr 26 |
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
|
Apr 26 |
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
|
Apr 26 |
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
|
Apr 26 |
Q1 2024 Bristol-Myers Squibb Co Earnings Call
|
Apr 26 |
Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat
|
Apr 25 |
Bristol Myers Squibb stock tumbles on cost-cutting initiative
|
Apr 25 |
Bristol-Myers Squibb Stock: Gloomy Q1 Earnings Trigger Justified Sell-Off
|
Apr 25 |
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
|
Apr 25 |
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
|